Therefore, lowering UA by inhibiting XO could attenuate the liver damage seen in NAFLD by suppressing NLRP3 inflammasome activation and both NOX- and XO-mediated ROS production. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.